No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 14517.1x · 10Y median 8424.4x · 90th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:33:06.891Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Genelux Corporation (GNLX) stock was $2.59 as of Oct 6, 2026, 11:31 AM EDT, down 0.38% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -41.4% · 3-year avg -52.8%/yr
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer.
Biotechnology · Westlake Village, CA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.20
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.21
vs Estimate
$-0.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GNLX | $116.14M | $2.59 | -0.38% | -41.42% | N/A | N/A | N/A |
| 2LUCD | $116.43M | $0.61 | +2.87% | -42.80% | N/A | N/A | vs GNLX |
| 3COYA | $116.58M | $4.97 | +2.47% | -20.40% | N/A | N/A | vs GNLX |
| 4CRBU | $117.53M | $1.19 | -0.42% | -47.42% | -44.43% | N/A | vs GNLX |
| 5FHTX | $117.82M | $2.01 | +0.33% | -56.72% | -31.87% | N/A | vs GNLX |
| 6IMDX | $118.02M | $3.65 | -0.41% | +9.50% | -44.39% | -29.11% | vs GNLX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 6 analysts
Average Price Target
$18.83
+627.2% upside
Low
$12.00
Current
$2.59
High
$31.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.21 | $-0.20 | $-0.19 | 4 |
| Quarter ending Dec 2026 | $-0.20 | $-0.20 | $-0.20 | 4 |
| Quarter ending Mar 2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Quarter ending Jun 2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.81 | $-0.81 | $-0.80 | 4 |
| FY 2027 | $-0.85 | $-0.75 | $-0.65 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $3.11M | $3.11M | $3.11M | 1 |
| Quarter ending Jun 2027 | $3.24M | $3.24M | $3.24M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.65M | $2.65M | $2.65M | 5 |
| FY 2027 | $7.85M | $7.85M | $7.85M | 4 |
